Material Insights · Understanding the Material World

GLP-1 receptor agonists: Evolution

Timeline

The milestones from first idea to today

YearMilestone
1987GLP-1 (7 to 37) is shown to trigger insulin release from the pancreas [1]
1992John Eng finds exendin-4 in Gila monster venom [2]
2005Exenatide (Byetta) is approved by the US Food and Drug Administration [2]
2010Liraglutide, a modified human GLP-1 lasting a day, is approved in the United States for diabetes [1]
2014Liraglutide is approved for obesity in the United States [1]
2017Semaglutide (Ozempic) is approved for diabetes; it is approved for obesity (Wegovy) in 2021 [1]
2023Tirzepatide, which also acts on a second gut hormone receptor (GIP), is approved for weight loss in the United States [1]
2025WHO adds GLP-1 medicines to its Essential Medicines List and issues a global guideline on their use for obesity [3]

as of 2026-11-11

Lineage

The technologies it came from and the ones that came from it

Works with
  • Inl Insulin therapy Both treat diabetes; GLP-1 drugs make the body release its own insulin when blood sugar is high [1].
Builds on

as of 2026-11-11

Sources

  1. GLP-1-based therapy for obesity Lasker Foundation (2024 Lasker~DeBakey Clinical Medical Research Award), 2024
  2. Dr. John Eng to Receive Golden Goose Award The Science Coalition, 2013
  3. WHO issues global guideline on the use of GLP-1 medicines in treating obesity World Health Organization, 2025